Lyra Therapeutics (LYRA) CEO Maria Palasis Returns 2,000 Shares to Company

What Happened

• Maria Palasis, Principal Executive Officer and Director of Lyra Therapeutics (LYRA), disposed of 2,000 shares back to the issuer on 2026-04-01. The reported price per share was $0.00, so the transaction produced $0 in cash proceeds.
• This was a disposition to the company (not an open-market sale). Dispositions to the issuer typically involve returning, surrendering, or canceling shares rather than selling them on the market.

Key Details

• Transaction date: 2026-04-01; Filing date: 2026-04-03 (filed within the typical 2-business-day Form 4 window).
• Transaction type/code: D — Disposition to issuer.
• Shares affected: 2,000; Reported price: $0.00; Cash proceeds: $0.
• Shares owned after the transaction: not specified in the provided transaction details.
• No footnotes, 10b5‑1 plan, or tax‑withholding notation was provided in the summary you shared.

Context

• A disposition to the issuer at $0 often reflects administrative actions (for example, share surrender or cancellation, or use of shares to satisfy obligations) rather than a sale that generates proceeds; it does not necessarily indicate insider sentiment about the company.
• For retail investors, purchases are more informative about insider confidence; a zero‑proceeds disposition is typically routine or administrative.